Introduction {#sec1_1}
============

In the past 2 decades, noninvasive measurements of arterial function are increasingly used as an intermediate measure of cardiovascular disease risk in therapeutic trials, such as antihypertensive therapy. Among various parameters of arterial function, pulse wave velocity and augmentation index measure arterial stiffness and wave reflections, respectively. Both measures can be accurately estimated within minutes with easy-to-use devices and may predict cardiovascular events above and beyond conventional cardiovascular risk factors, such as high blood pressure \[[@B1],[@B2]\]. However, at present, there is no specific treatment for increased arterial stiffness or wave reflections. Nonetheless, antihypertensive drugs, especially those of vasodilatating action, seem to be promising in this regard.

Since the early 1990s, several randomized controlled trials have been conducted to study the effects of various antihypertensive drugs on carotid-femoral or brachial-ankle pulse wave velocity and augmentation index. In the present review article, we summarized these trials to investigate whether and which antihypertensive drugs are efficacious in reducing arterial stiffness and wave reflections and to explore the clinical relevance of these arterial measurements for cardiovascular protection and prevention.

Arterial Effects of Antihypertensive Drugs in Placebo-Controlled Trials {#sec1_2}
=======================================================================

Of the 27 placebo-controlled trials, 11 had a cross-over design (table [1](#T1){ref-type="table"}) \[[@B3],[@B4],[@B5],[@B6],[@B7],[@B8],[@B9],[@B10],[@B11],[@B12],[@B13]\] and 16 had a parallel-group comparison design (table [2](#T2){ref-type="table"}) \[[@B14],[@B15],[@B16],[@B17],[@B18],[@B19],[@B20],[@B21],[@B22],[@B23],[@B24],[@B25],[@B26],[@B27],[@B28],[@B29]\]. Regardless of the design, these placebo-controlled studies had a sample size of tens and a follow-up time of weeks.

Of the 11 placebo-controlled cross-over trials, 6 and 5 had single \[[@B8],[@B9],[@B10],[@B11],[@B12],[@B13]\] and multiple comparisons with placebo \[[@B3],[@B4],[@B5],[@B6],[@B7]\], respectively, and 2, 4, and 5 studied pulse wave velocity \[[@B11],[@B13]\], augmentation index alone \[[@B4],[@B5],[@B7],[@B10]\], and both \[[@B3],[@B6],[@B8],[@B9],[@B12]\], respectively (table [1](#T1){ref-type="table"}). The results of these trials were generally consistent across various classes of antihypertensive drugs for pulse wave velocity but not augmentation index. Antihypertensive drugs were efficacious in reducing pulse wave velocity. However, most drugs had neutral effects on augmentation index, and β-blockers even had worse effects than placebo on this measure of wave reflections \[[@B6],[@B12]\].

Of the 16 placebo-controlled parallel-group comparison trials, 12 and 4 had single \[[@B15],[@B17],[@B18],[@B19],[@B20],[@B21],[@B22],[@B24],[@B25],[@B27],[@B28],[@B29]\] and multiple comparisons with placebo \[[@B14],[@B16],[@B23],[@B26]\], respectively, and 8, 3, and 5 studied pulse wave velocity \[[@B14],[@B16],[@B19],[@B24],[@B25],[@B26],[@B27],[@B28]\], augmentation index alone \[[@B15],[@B18],[@B23]\], and both \[[@B17],[@B20],[@B21],[@B22],[@B29]\], respectively (table [2](#T2){ref-type="table"}). The results of these parallel-group comparison trials were confirmatory for pulse wave velocity. Antihypertensive drugs significantly reduced pulse wave velocity in 10 of 18 drug comparisons from 13 trials. However, the results of these trials were slightly different for augmentation index. Antihypertensive drugs significantly reduced pulse wave velocity in 4 of 10 drug comparisons from 8 trials, none of which used β-blockers.

Arterial Effects of Antihypertensive Drugs in Actively-Controlled Trials {#sec1_3}
========================================================================

The actively-controlled trials also included those studies involving 2 or more drug comparisons with placebo. Of the 15 trials with a cross-over design (table [3](#T3){ref-type="table"}) \[[@B1],[@B2],[@B3],[@B4],[@B5],[@B10],[@B30],[@B31],[@B32],[@B33],[@B34],[@B35],[@B36],[@B37],[@B38]\] and 31 trials with a parallel-group comparison design (table [4](#T4){ref-type="table"}) \[[@B13],[@B16],[@B23],[@B26],[@B39],[@B40],[@B41],[@B42],[@B43],[@B44],[@B45],[@B46],[@B47],[@B48],[@B49],[@B50],[@B51],[@B52],[@B53],[@B54],[@B55],[@B56],[@B57],[@B58],[@B59],[@B60],[@B61],[@B62],[@B63],[@B64],[@B65]\], 6 \[[@B1],[@B2],[@B3],[@B4],[@B5],[@B10]\] and 4 \[[@B13],[@B16],[@B23],[@B26]\], respectively, were part of placebo-controlled studies. These actively-controlled studies also had a small sample size and short follow-up time with the exception of the CAFE (n = 2,073) \[[@B61]\], EXPLORE (n = 331) \[[@B50]\], and REASON trials (n = 406) \[[@B65]\]. These bigger studies investigated combination therapy and (except REASON \[[@B65]\]) had an open design, and hence had limited information on the comparison between drug classes.

Of the cross-over trials, 2, 7, and 6 studied pulse wave velocity \[[@B31],[@B37]\], augmentation index alone \[[@B2],[@B3],[@B5],[@B32],[@B33],[@B36],[@B38]\], and both \[[@B1],[@B4],[@B10],[@B30],[@B34],[@B35]\], respectively (table [3](#T3){ref-type="table"}). These trials included 15 comparisons of angiotensin-converting enzyme (ACE) inhibitors with angiotensin receptor blockers (ARBs; n = 3) \[[@B5],[@B30],[@B31]\], β-blockers (n = 7) \[[@B1],[@B2],[@B3],[@B4],[@B32],[@B33],[@B34]\], calcium channel blockers (CCBs; n = 3) \[[@B2],[@B3],[@B33]\], and diuretics (n = 2) \[[@B2],[@B3]\], 2 comparisons of ARBs with β-blockers \[[@B35],[@B36]\], 6 comparisons between 2 different β-blockers (n = 1) \[[@B10]\] or of β-blockers with CCBs (n = 3) \[[@B2],[@B3],[@B33]\] and diuretics (n = 2) \[[@B2],[@B3]\], 3 comparisons of CCBs with diuretics \[[@B2],[@B3],[@B37]\], and 2 comparisons of combination therapy with each of their component drugs \[[@B30],[@B38]\]. In these short-term cross-over studies, antihypertensive drugs had similar arterial effects, except that β-blockers were inferior to the other classes of antihypertensive drugs in reducing augmentation index in 11 of 14 comparisons with ACE inhibitors, ARBs, CCBs, or diuretics.

Of the parallel group trials, 20, 4, and 7 studied pulse wave velocity \[[@B13],[@B16],[@B26],[@B39],[@B40],[@B41],[@B42],[@B43],[@B46],[@B47],[@B49],[@B52],[@B53],[@B54],[@B55],[@B56],[@B58],[@B59],[@B60],[@B62]\], augmentation index alone \[[@B23],[@B48],[@B57],[@B63]\], and both \[[@B44],[@B45],[@B50],[@B51],[@B61],[@B64],[@B65]\], respectively (table [4](#T4){ref-type="table"}). These trials included 20 comparisons of ACE inhibitors with ARBs (n = 6) \[[@B16],[@B39],[@B40],[@B41],[@B42],[@B43]\], β-blockers (n = 2) \[[@B13],[@B44]\], CCBs (n = 8) \[[@B13],[@B39],[@B40],[@B43],[@B44],[@B45],[@B46]\], and diuretics (n = 4) \[[@B44],[@B47],[@B48],[@B49]\], 13 comparisons of ARBs with β-blockers (n = 2) \[[@B50],[@B51]\], CCBs (n = 10) \[[@B39],[@B40],[@B43],[@B52],[@B53],[@B54],[@B55],[@B56],[@B57],[@B58]\], or a diuretic (n = 1) \[[@B23]\], 5 comparisons of β-blockers with CCBs (n = 4) \[[@B13],[@B26],[@B44],[@B59]\] or a diuretic (n = 1) \[[@B44]\], 7 comparisons between 2 different CCBs (n = 1) \[[@B40]\] or of CCBs with diuretics (n = 6) \[[@B44],[@B60],[@B61],[@B62],[@B63],[@B64]\], and 2 comparisons of combination therapy with one \[[@B65]\] or two of their component drugs \[[@B41]\]. In these studies, ACE inhibitors or ARBs tended to be more efficacious than other classes of antihypertensive drugs in reducing arterial stiffness, especially when brachial-ankle pulse wave velocity was measured in 11 trials \[[@B16],[@B40],[@B41],[@B43],[@B46],[@B52],[@B53],[@B54],[@B56],[@B58],[@B62]\]. The results were not consistent for other comparisons of pulse wave velocity or for studies on augmentation index, except that β-blockers were inferior to the other classes of antihypertensive drugs in reducing augmentation index in all 5 comparisons with an ACE inhibitor (n = 1) \[[@B44]\], ARBs (n = 2) \[[@B50],[@B51]\], a CCB (n = 1) \[[@B44]\], or a diuretic (n = 1) \[[@B44]\].

Conclusions and Perspectives {#sec1_4}
============================

Our narrative review was informative on three clinically relevant questions. First, antihypertensive drugs are effective in reducing arterial stiffness. However, this effect does not at all infer any benefit above and beyond blood pressure lowering. In contrast, because pulse wave velocity is dependent on systolic blood pressure, the therapeutic effect of antihypertensive drugs on arterial stiffness, to some extent if not entirely, can be attributable to their blood pressure lowering efficacy. Second, though all antihypertensive drugs reduce arterial stiffness, ACE inhibitors or ARBs might be more efficacious than other classes of antihypertensive drugs. This effect is more evident when brachial-ankle pulse wave velocity is measured. The mechanism remains to be elucidated. Third, as also evidenced by a recent meta-analysis of randomized controlled trials that compared β-blockers with the other classes of antihypertensive drugs \[[@B66]\], because of the intrinsic heart rate slowing effect, β-blockers are inferior to all the other classes of antihypertensive drugs in reducing augmentation index. However, whether this inferiority is clinically relevant for cardiovascular protection and prevention remains to be investigated.

In spite of a large number of trials that studied the efficacy of antihypertensive drugs in reducing pulse wave velocity and augmentation index, these studies had a small sample size and a short follow-up time and did not link the changes in measurements of arterial function with cardiovascular events. It is therefore imperative to combine the research force in the field of arterial functions to run adequately powered outcome trials to investigate whether arterial stiffness and wave reflections are clinically useful in monitoring the effect of antihypertensive treatment and other cardiovascular therapeutic approaches.
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###### 

Randomized placebo-controlled double-blind cross-over studies

  First author \[Ref.\]   Year   Subjects                 Patients, n   Antihypertensive treatment(s)   Results                                      
  ----------------------- ------ ------------------------ ------------- ------------------------------- -------------------------------------------- ----------------------------------------
  *ACEIs*                                                                                                                                            
  Pannier \[[@B3]\]       2001   EH                       20            perindopril                     AUC cfPWV NS                                 AUC AIx perindopril better
  Deary \[[@B4]\]         2002   EH                       30            lisinopril                      not measured                                 AIx NS
  Morgan \[[@B5]\]        2004   EH                       32            ACEIs                           not measured                                 AIx NS
  Hirata \[[@B6]\]        2005   CAD                      30            ramipril                        cfPWV ramipril better                        AIx and AIx\@HR75 ramipril better
  Turner \[[@B7]\]        2006   intracranial aneurysms   19            perindopril                     not measured                                 AIx NS
                                                                                                                                                     
  *ARBs*                                                                                                                                             
  Asmar \[[@B8]\]         2002   EH/DM                    20            telmisartan                     cfPWV telmisartan better                     AIx NS
  Rajagopalan \[[@B9]\]   2006   healthy volunteers       33            valsartan                       cfPWV NS                                     AIx NS
  Turner \[[@B7]\]        2006   intracranial aneurysms   19            irbesartan                      not measured                                 AIx NS
  Kaufman \[[@B10]\]      2010   EH                       10            losartan                        not measured                                 AIx NS
                                                                                                                                                     
  *β-Blockers*                                                                                                                                       
  Asmar \[[@B11]\]        1991   EH                       14            bisoprolol                      cfPWV bisoprolol better                      not measured
  Pannier \[[@B3]\]       2001   EH                       20            atenolol                        AUC cfPWV atenolol better                    AUC AIx NS
  Deary \[[@B4]\]         2002   EH                       30            bisoprolol                      not measured                                 AIx bisoprolol better
  Morgan \[[@B5]\]        2004   EH                       32            β-blockers                      not measured                                 AIx NS
  Hirata \[[@B6]\]        2005   CAD                      30            atenolol                        cfPWV atenolol better                        AIx atenolol worse; AIx\@HR75 NS
  Dhakam \[[@B12]\]       2008   EH                       16            nebivolol atenolol              aPWV nebivolol better aPWV atenolol better   AIx nebivolol worse AIx atenolol worse
                                                                                                                                                     
  *CCBs*                                                                                                                                             
  Deary \[[@B4]\]         2002   EH                       30            amlodipine                      not measured                                 AIx NS
  Morgan \[[@B5]\]        2004   EH                       32            CCBs                            not measured                                 AIx NS
                                                                                                                                                     
  *Diuretics*                                                                                                                                        
  Deary \[[@B4]\]         2002   EH                       30            bendrofluazide                  not measured                                 AIx NS
  Morgan \[[@B5]\]        2004   EH                       32            diuretics                       not measured                                 AIx NS
  Davies \[[@B13]\]       2005   EH/DM                    10            spironolactone                  crPWV spironolactone better                  not measured

ACEIs = ACE inhibitors; AIx = augmentation index; AIx\@HR75 = AIx corrected for heart rate of 75 beats/min; aPWV = aortic pulse wave velocity; AUC = area under the curve; CAD = coronary artery disease; cfPWV = carotid-femoral pulse wave velocity; crPWV = carotid-radial pulse wave velocity; DM = diabetes mellitus; EH = essential hypertension; NS = not significantly different.

###### 

Randomized placebo-controlled parallel-group comparison studies

  First author \[Ref.\]   Year   Design   Subjects                   Patients, n   Antihypertensive treatment(s)             Results                                                     
  ----------------------- ------ -------- -------------------------- ------------- ----------------------------------------- ----------------------------------------------------------- ---------------------------
  *ACEIs*                                                                                                                                                                                
  Kahonen \[[@B14]\]      1998   DB       healthy volunteers         15            captopril                                 cfPWV captopril better                                      not measured
  Dart \[[@B15]\]         2001   open     EH                         111           perindopril                               not measured                                                AIx NS
  Ichihara \[[@B16]\]     2005   --       hemodialysis patients      42            trandolapril                              baPWV trandolapril better                                   not measured
  Yu \[[@B17]\]           2006   DB       hemodialysis patients      46            ramipril                                  cfPWV NS                                                    AIx NS
  Tsang \[[@B18]\]        2006   DB       IDD                        21            quinapril                                 not measured                                                AIx NS
  Ahimastos \[[@B19]\]    2007   DB       Marfan syndrome            17            perindopril                               cfPWV and faPWV perindopril better                          not measured
  Rahman \[[@B20]\]       2007   DB       DM                         19            ramipril                                  cfPWV NS                                                    AIx NS
                                          IGT                        21            ramipril                                  cfPWV NS                                                    AIx ramipril better
  Mitchell \[[@B21]\]     2007   open     CAD                        300           trandolapril                              cfPWV trandolapril better                                   AIx NS
  Ahimastos \[[@B22]\]    2008   DB       PAD                        40            ramipril                                  cfPWV ramipril better                                       AIx ramipril better
                                                                                                                                                                                         
  *ARBs*                                                                                                                                                                                 
  Klingbeil \[[@B23]\]    2002   DB       EH                         40            valsartan                                 not measured                                                AIx valsartan better
  Ichihara \[[@B16]\]     2005   --       hemodialysis patients      43            losartan                                  baPWV NS                                                    not measured
  Mitsuhashi \[[@B24]\]   2009   --       EH/hemodialysis patients   40            losartan                                  baPWV NS                                                    not measured
                                                                                                                                                                                         
  *ß-Blockers*                                                                                                                                                                           
  Kahonen \[[@B14]\]      1998   DB       healthy volunteers         15            propranolol                               cfPWV propranolol better                                    not measured
  Kahonen \[[@B25]\]      2000   DB       healthy volunteers         31            bisoprolol, celiprolol, and propranolol   cfPWV bisoprolol and propranolol better; celiprolol worse   not measured
  Ylitalo \[[@B26]\]      2005   DB       healthy volunteers         18            bisoprolol                                cfPWV NS                                                    not measured
                                                                                                                                                                                         
  *CCBs*                                                                                                                                                                                 
  London \[[@B27]\]       1990   DB       ESRD                       37            nitrendipine                              cfPWV nitrendipine better                                   not measured
  Asmar \[[@B28]\]        1992   DB       EH                         17            nitrendipine                              cfPWV nitrendipine better                                   not measured
  Kahonen \[[@B14]\]      1998   DB       healthy volunteers         15            verapamil                                 cfPWV NS                                                    not measured
  Ylitalo \[[@B26]\]      2005   DB       healthy volunteers         17            nisoldipine                               cfPWV NS                                                    not measured
                                                                                                                                                                                         
  *Diuretics*                                                                                                                                                                            
  Klingbeil \[[@B23]\]    2002   DB       EH                         40            hydrochlorothiazide                       not measured                                                AIx NS
  Edwards \[[@B29]\]      2009   DB       CKD                        112           spironolactone                            cfPWV spironolactone better                                 AIx spironolactone better

ACEIs = ACE inhibitors; AIx = augmentation index; baPWV = brachial-ankle pulse wave velocity; CAD = coronary artery disease; cfPWV = carotid-femoral pulse wave velocity; CKD = chronic kidney disease; DB = double-blinded; DM = diabetes mellitus; EH = essential hypertension; ESRD = end-stage renal dysfunction; faPWV = femoral-dorsalis pedis pulse wave velocity; IDD = isolated diastolic dysfunction; IGT = impaired glucose tolerance; NS = not significantly different; PAD = peripheral artery disease.

###### 

Randomized actively-controlled cross-over studies

  First author \[Ref.\]   Year   Design   Subjects                   Patients, n   Comparison(s)                                                    Results                    
  ----------------------- ------ -------- -------------------------- ------------- ---------------------------------------------------------------- -------------------------- -----------------------------------
  ACEIs                                                                                                                                                                        
  *vs. ARBs*                                                                                                                                                                   
  Mahmud \[[@B30]\]       2002   SB       EH                         12            captopril vs. valsartan                                          cfPWV NS                   AIx NS
  Turner \[[@B7]\]        2006   DB       intracranial aneurysms     19            perindopril vs. irbesartan                                       not measured               AIx NS
  Ali \[[@B31]\]          2009   DB       EH                         15            lisinopril vs. irbesartan                                        cfPWV NS                   not measured
                                                                                                                                                                               
  *vs. ß-blockers*                                                                                                                                                             
  Chen \[[@B32]\]         1995   DB       EH                         79            fosinopril vs. atenolol                                          not measured               AIx fosinopril better
  Pannier \[[@B3]\]       2001   DB       EH                         20            perindopril vs. atenolol                                         cfPWV atenolol             AUC AIx per-idopril
                                                                                                                                                    better                     better
  Deary \[[@B4]\]         2002   DB       EH                         30            lisinopril vs. bisoprolol                                        not measured               AIx lisinopril better
  Morgan \[[@B5]\]        2004   DB       EH                         32            ACEIs vs. β-blockers                                             not measured               AIx ACEIs better
  Neal \[[@B33]\]         2004   DB       EH/liver transplantation   12            lisinopril vs. bisoprolol                                        not measured               AIx lisinopril better
  Hirata \[[@B6]\]        2005   DB       CAD                        30            ramipril vs. atenolol                                            cfPWV NS                   AIx and AIx\@HR75 ramipril better
  Kaiser \[[@B34]\]       2006   DB       EH/DM                      10            enalapril vs. nebivolol                                          cfPWV NS                   AIx NS
                                                                                                                                                                               
  *vs. CCBs*                                                                                                                                                                   
  Deary \[[@B4]\]         2002   DB       EH                         30            lisinopril vs. amlodipine                                        not measured               AIx NS
  Morgan \[[@B5]\]        2004   DB       EH                         32            ACEIs vs. CCBs                                                   not measured               AIx NS
  Neal \[[@B33]\]         2004   DB       EH/liver transplantation   12            lisinopril vs. amlodipine                                        not measured               AIx NS
                                                                                                                                                                               
  *vs. diuretics*                                                                                                                                                              
  Deary \[[@B4]\]         2002   DB       EH                         30            lisinopril vs. bendrofluazide                                    not measured               AIx NS
  Morgan \[[@B5]\]        2004   DB       EH                         32            ACEIs vs. diuretics                                              not measured               AIx NS
                                                                                                                                                                               
  **ARBs**                                                                                                                                                                     
  *vs. ß-blockers*                                                                                                                                                             
  Dhakam \[[@B35]\]       2006   DB       EH                         21            eprosartan vs. atenolol                                          cfPWV atenolol better      AIx eprosartan better
  Izzo \[[@B36]\]         2012   SB       EH                         30            lisinopril + valsartan vs. lisinopril + carvedilol               not measured               AIx NS
                                                                                                                                                                               
  **β-Blockers**                                                                                                                                                               
  *vs. ß-blockers*                                                                                                                                                             
  Dhakam \[[@B12]\]       2008   DB       EH                         16            atenolol vs. nebivolol                                           aPWV NS                    AIx nebivolol better
                                                                                                                                                                               
  *vs. CCBs*                                                                                                                                                                   
  Deary \[[@B4]\]         2002   DB       EH                         30            bisoprolol vs. amlodipine                                        not measured               AIx amlodipine better
  Morgan \[[@B5]\]        2004   DB       EH                         32            ß-blockers vs. CCBs                                              not measured               AIx CCBs better
  Neal \[[@B33]\]         2004   DB       EH/liver transplantation   12            bisoprolol vs. amlodipine                                        not measured               AIx NS
                                                                                                                                                                               
  *vs. diuretics*                                                                                                                                                              
  Deary \[[@B4]\]         2002   DB       EH                         30            bisoprolol vs. bendrofluazide                                    not measured               AIx bendrofluazide better
  Morgan \[[@B5]\]        2004   DB       EH                         32            ß-blockers vs. diuretics                                         not measured               AIx diuretics better
                                                                                                                                                                               
  **CCBs**                                                                                                                                                                     
  *vs. diuretics*                                                                                                                                                              
  Asmar \[[@B37]\]        1993   DB       EH                         16            felodipine vs. hydrochlorothiazide                               cfPWV felodipine better    not measured
  Deary \[[@B4]\]         2002   DB       EH                         30            amlodipine vs. bendrofluazide                                    not measured               AIx NS
  Morgan \[[@B5]\]        2004   DB       EH                         32            CCBs vs. diuretics                                               not measured               AIx NS
                                                                                                                                                                               
  **Other**                                                                                                                                                                    
  Mahmud \[[@B30]\]       2002   SB       EH                         12            captopril + valsartan vs. captopril vs. valsartan                cfPWV combination better   AIx combination better
  Ferguson \[[@B38]\]     2008   DB       EH                         22            fosinopril + hydrochlorothiazide vs. amlodipine vs. indapamide   not measured               AIx combination better

ACEIs = ACE inhibitors; AIx = augmentation index; AIx\@HR75 = AIx corrected for heart rate of 75 beats/min; aPWV = aortic pulse wave velocity; AUC = area under the curve; CAD = coronary artery disease; cfPWV = carotid-femoral pulse wave velocity; DB = double-blinded; DM = diabetes mellitus; EH = essential hypertension; NS = not significantly different; SB = single-blinded.

###### 

Randomized actively-controlled parallel-group comparison studies

  First author                    Year   Design   Subjects                Patients, n   Comparison(s)                                           Results                     
  ------------------------------- ------ -------- ----------------------- ------------- ------------------------------------------------------- --------------------------- ---------------------------------------
  **ACEIs**                                                                                                                                                                 
  *vs. ARBs*                                                                                                                                                                
  Rajzer \[[@B39]\]               2003   open     EH                      62            quinapril vs. losartan                                  cfPWV quinapril better      not measured
  Takami \[[@B40]\]               2003   SB       EH                      40            temocapril vs. valsartan                                baPWV valsartan better      not measured
  Ichihara \[[@B16]\]             2005   SB       hemodialysis patients   43            trandolapril vs. losartan                               baPWV NS                    not measured
  Anan \[[@B41]\]                 2005   SB       EH                      21            perindopril vs. valsartan                               baPWV NS                    not measured
  Rehman \[[@B42]\]               2007   DB       EH                      39            perindopril vs. losartan                                cfPWV NS                    not measured
  Li \[[@B43]\]                   2009   SB       EH                      68            perindopril vs. telmisartan                             baPWV telmisartan better    not measured
                                                                                                                                                                            
  *vs. ß-blockers*                                                                                                                                                          
  Kahonen \[[@B14]\]              1998   DB       healthy volunteers      15            captopril vs. propranolol                               aPWV NS                     not measured
  Mackenzie \[[@B44]\]            2009   DB       EH                      32            perindopril vs. atenolol                                cfPWV NS                    AIx perindopril better
                                                                                                                                                                            
  *vs. CCBs*                                                                                                                                                                
  London \[[@B45]\]               1994   SB       ESRD                    24            perindopril vs. nitrendipine                            cfPWV NS                    AIx NS
  Kahonen \[[@B14]\]              1998   DB       healthy volunteers      15            captopril vs. verapamil                                 aPWV NS                     not measured
  Rajzer \[[@B39]\]               2003   open     EH                      75            quinapril vs. amlodipine                                cfPWV quinapril better      not measured
  Takami \[[@B40]\]               2003   --       EH                      40            temocapril vs. cilnidipine                              baPWV NS                    not measured
                                                                          36            temocapril vs. nifedipine                               baPWV temocapril better     not measured
  Morimoto \[[@B46]\]             2008   --       EH                      32            ARB + perindopril vs. ARB + amlodipine                  baPWV NS                    not measured
  Mackenzie \[[@B44]\]            2009   DB       EH                      29            perindopril vs. lercanidipine                           cfPWV NS                    AIx NS
  Li \[[@B43]\]                   2009   SB       EH                      68            perindopril vs. amlodipine                              baPWV amlodipine better     not measured
                                                                                                                                                                            
  *vs. diuretics*                                                                                                                                                           
  Breithaupt-Grogler \[[@B47]\]   1996   DB       EH                      17            cilazapril vs. hydrochlorothiazide                      cfPWV NS                    not measured
  Jiang \[[@B48]\]                2005   DB       EH                      101           enalapril vs. indapamide                                not measured                AIx enalapril better
  Mackenzie \[[@B44]\]            2009   DB       EH                      28            perindopril vs. bendrofluazide                          cfPWV NS                    AIx NS
  Kostka-Jeziorny \[[@B49]\]      2011   open     EH                      66            perindopril vs. hydrochlorothiazide                     cfPWV NS                    not measured
                                                                                                                                                                            
  **ARBs**                                                                                                                                                                  
  *vs. ß-blockers*                                                                                                                                                          
  Boutouyrie \[[@B50]\]           2010   open     EH                      331           amlodipine + valsartan vs. amlodipine + atenolol        cfPWV NS                    AIx and AIx\@HR75 valsartan better
  Vitale \[[@B51]\]               2012   DB       EH                      65            irbesartan vs. nebivolol                                cfPWV NS                    AIx irbesartan better; AIx\@HR75 NS
                                                                                                                                                                            
  *vs. CCBs*                                                                                                                                                                
  Rajzer \[[@B39]\]               2003   open     EH                      61            losartan vs. amlodipine                                 cfPWV NS                    not measured
  Takami \[[@B40]\]               2003   --       EH                      40            valsartan vs. cilnidipine vs. nifedipine                baPWV valsartan better      not measured
  Munakata \[[@B52]\]             2004   --       EH                      41            valsartan vs. nifedipine                                baPWV valsartan better      not measured
  Ichihara \[[@B53]\]             2006   --       EH                      100           valsartan vs. amlodipine                                baPWV NS                    not measured
  Morimoto \[[@B54]\]             2006   --       EH                      43            telmisartan vs. amlodipine                              baPWV telmisartan better    not measured
  Kosch \[[@B55]\]                2008   DB       EH                      52            valsartan vs. metoprolol                                cfPWV NS                    not measured
  Ishii \[[@B56]\]                2008   --       EH/DM                   22            candesartan vs. CCBs                                    baPWV candesartan better    not measured
  Schneider \[[@B57]\]            2008   DB       EH                      156           irbesartan vs. atenolol                                 not measured                AIx irbesartan better
  Li \[[@B43]\]                   2009   SB       EH                      68            telmisartan vs. amlodipine                              baPWV telmisartan better    not measured
  Tomiyama \[[@B58]\]             2011   --       EH                      113           candesartan vs. amlodipine                              baPWV candesartan better    not measured
                                                                                                                                                                            
  *vs. diuretics*                                                                                                                                                           
  Klingbeil \[[@B23]\]            2002   DB       EH                      40            valsartan vs. hydrochlorothiazide                       not measured                AIx valsartan better
                                                                                                                                                                            
  **β-Blockers**                                                                                                                                                            
  *vs. CCBs*                                                                                                                                                                
  Merli \[[@B59]\]                1993   DB       EH                      28            metoprolol vs. isradipine                               cfPWV isradipine better     not measured
  Kahonen \[[@B14]\]              1998   DB       healthy                 15            propranolol vs. verapamil volunteers                    cfPWV propranolol better    not measured
  Ylitalo \[[@B26]\]              2005   DB       healthy volunteers      18            bisoprolol vs. nisoldipine                              cfPWV NS                    not measured
  Mackenzie \[[@B44]\]            2009   DB       EH                      31            atenolol vs. lercanidipine                              cfPWV NS                    AIx lercanidipine better
                                                                                                                                                                            
  *vs. diuretics*                                                                                                                                                           
  Mackenzie \[[@B44]\]            2009   DB       EH                      30            atenolol vs. bendrofluazide                             cfPWV NS                    AIx bendrofluazide better
                                                                                                                                                                            
  **CCBs**                                                                                                                                                                  
  *vs. CCBs*                                                                                                                                                                
  Takami \[[@B40]\]               2003   --       EH                      36            cilnidipine vs. nifedipine                              baPWV cilnidipine better    not measured
                                                                                                                                                                            
  *vs. diuretics*                                                                                                                                                           
  White \[[@B60]\]                2003   DB       EH                      139           amlodipine vs. eplerenone                               cfPWV NS                    not measured
  Williams \[[@B61]\]             2006   open     EH                      2,073         amlodipine vs. atenolol                                 cfPWV NS (n = 114)          AIx amlodipine better
  Kaneshiro \[[@B62]\]            2009   DB       CKD                     68            valsartan + amlodipine vs. valsartan + thiazide         baPWV NS                    not measured
  Mackenzie \[[@B44]\]            2009   DB       EH                      27            lercanidipine vs. bendrofluazide                        cfPWV NS                    AIx NS
  Doi \[[@B63]\]                  2010   open     EH                      37            azelnidipine vs. trichlormethiazide                     not measured                AIx and AIx\@HR75 azelnidipine better
  Matsui \[[@B64]\]               2011   open     EH                      207           azelnidipine vs. hydrochlorothiazide                    cfPWV azelnidipine better   AIx NS
                                                                                                                                                                            
  **Other**                                                                                                                                                                 
  Asmar \[[@B65]\]                2001   DB       EH                      406           perindopril + indapamide vs. atenolol                   cfPWV NS                    AIx combination better
  Anan \[[@B41]\]                 2005   ^--^     EH                      21            perindopril + valsartan vs. perindopril vs. valsartan   baPWV combination better    not measured

ACEIs = ACE inhibitors; AIx = augmentation index; AIx\@HR75 = AIx corrected for heart rate of 75 beats/min; aPWV = aortic pulse wave velocity; baPWV = brachial-ankle pulse wave velocity; cfPWV = carotid-femoral pulse wave velocity; CKD = chronic kidney disease; DB = double-blinded; DM = diabetes mellitus; EH = essential hypertension; ESRD = end-stage renal dysfunction; NS = not significantly different; SB = single-blinded.
